Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ: NKTR) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) concerning whether a series of statements by Nektar Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On October 1, 2018, a report published by Plainview LLC raised questions about Nektar’s claims concerning its clinical stage drug, NKTR-214, and its ability to effectively treat cancer.

Following this report, the Company's stock price plunged more than 11% over the next two days.

Based in San Francisco, California, and founded in 1990 Nektar Therapeutics discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States.

If you purchased shares of Nektar Therapeutics (NASDAQ: NKTR) on or before October 1, 2018, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185